Systems and methods for administering dermal and transdermal immunotherapy topical application compounds to animals

Abstract

A method for treating an allergy condition of an animal includes detecting that the animal has one or more allergy condition, where the one or more allergy condition comprises one or more plant-based allergen, one or more mold or fungus-based allergen, one or more mite or insect-based allergen, or a combination thereof. The method includes determining a first quantity of a topical application medium and a first quantity of the one or more allergens based at least in part on one or more attributes of the animal. The method includes providing a first topical application compound, the first topical application compound comprising the first quantity of the one or more allergens and the first quantity of the topical application medium. The method includes applying the first topical application compound to the animal to treat the allergy condition.

Description

[0001] Attorney Docket: 091665.0105

[0002] SYSTEMS AND METHODS FOR ADMINISTERING DERMAL AND TRANSDERMAL IMMUNOTHERAPY TOPICAL APPLICATION COMPOUNDS TO ANIMALS

[0003] FIELD OF THE INVENTION

[0004] The present disclosure relates to a system and methods for providing a more psychologically benign method of administering allergy medication to animals for whom traditional medication administration methods are unsuitable (for example and without limitation, needle-phobic animals), or more specifically to an immunotherapy method whereby allergens are administered to dogs and cats dermally or transdermally via a topical application compound such as a cream, gel, or oil.

[0005] BACKGROUND

[0006] Existing methods of immunotherapy are unsuitable for many household pets. Allergen-specific immunotherapy (commonly referred to as AIT) is accomplished by introducing small amounts of an allergen in a controlled manner until the patient becomes desensitized to the allergen. For dogs and cats, the primary manner by which allergens are introduced is via subcutaneous immunotherapy, in which a needle injects the allergen under the skin. It is not uncommon for dogs and cats to be afraid of needles. This fear can cause otherwise friendly dogs and cats to become uncooperative or aggressive, thereby impeding administration of the medication and creating a danger to any nearby veterinarians, veterinary technicians, or owners, as well as the animal. Further, this fear can cause the dog or cat to form a negative association with medical care. Beyond making administration of medication more cumbersome, inefficient, and dangerous, some patients feel that a pet’s negative association with medical care may adversely affect the human-animal bond in the home environment.

[0007] Sublingual immunotherapy has been used as an alternative to subcutaneous immunotherapy, but it is problematic for many owners and animals. Sublingual immunotherapy is practiced by administering oral -glycerinated allergens to the oral cavity, typically under the tongue. Though sublingual immunotherapy boasts similar efficacy to subcutaneous immunotherapy when practiced correctly, it is impeded by four barriers to correct administration. First, sublingual immunotherapy is hampered by a lesser version of the same major drawback as subcutaneous immunotherapy — that is, it is common for animals to be averse to having medication placed underneath their tongues, and this aversion can create a negative association with medical care. Second, sublingual immunotherapy generally requires Attorney Docket: 091665.0105 two daily administrations, which can be difficult for clients with schedules that conflict with the requisite administration timing. Third, food and water must be restricted for up to thirty minutes to prevent interference with the absorption of allergens. Fourth, the efficacy of sublingual immunotherapy is severely impeded if the animal swallows the allergens before the allergens are sufficiently absorbed across the mucous membranes. In short, sublingual immunotherapy serves as a substitute to subcutaneous immunotherapy for animals in some cases, but both methods are ill-suited to a significant percentage of dogs and cats.

[0008] BRIEF DESCRIPTION OF THE DRAWINGS

[0009] A more complete understanding of the present embodiments and advantages thereof may be acquired by referring to the following description taken in conjunction with the accompanying drawings, in which like reference numbers indicate like features.

[0010] FIG. 1 depicts an exemplary illustration of an immunotherapy topical application compound being applied transdermally to the pinna of a dog’s ear, according to one or more aspects of the present disclosure.

[0011] FIG. 2 depicts an exemplary7diagram of a method for creating serial dilutions of an immunotherapy topical application compound, according to one or more aspects of the present disclosure.

[0012] FIG. 3 depicts an exemplary7flow diagram illustrating a method for creating and administering a dermal or transdermal immunotherapy topical application compound, according to one or more aspects of the present disclosure.

[0013] FIG. 4 depicts a schematic diagram of an information handling system for use with the production and administration of medication, according to one or more aspects of the present disclosure.

[0014] FIG. 5 depicts an exemplary flow diagram illustrating a method for creating and administering a dermal or transdermal immunotherapy topical application compound, according to one or more aspects of the present disclosure.

[0015] FIG. 6 depicts an exemplary flow diagram illustrating a method for determining an allergy7status of an animal, according to one or more aspects of the present disclosure. Attorney Docket: 091665.0105

[0016] While embodiments of this disclosure have been depicted and described and are defined by reference to exemplary embodiments of the disclosure, such references do not imply a limitation on the disclosure and no such limitation is to be inferred. The subject matter disclosed is capable of considerable modification, alteration, and equivalents in form and function, as will occur to those skilled in the pertinent art and having the benefit of this disclosure. The depicted and described embodiments of this disclosure are examples only and are not exhaustive of the scope of the disclosure.

[0017] DETAILED DESCRIPTION

[0018] The present disclosure relates to a system and methods for providing a more psychologically benign method of administering allergy’ medication to animals for whom traditional medication administration methods are unsuitable (for example and without limitation, needle-phobic animals), or more specifically to an immunotherapy method whereby allergens are administered to dogs and cats dermally or transdermally via a topical application compound.

[0019] Described herein is a technique for administering a dermal or transdermal immunotherapy topical application compound to animals. The disclosed methods and systems may be practiced by administering a small amount of an allergen dispersed into a cream, gel, or oil to either (1) the pinna of an animal’s ear; or (2) another location on an animal’s skin at which the topical application compound is unlikely to be rubbed or licked away. The allergen may be diluted into a diluent (for example and without limitation, one or more of human serum albumin (HSA), sterile water, sterile water with phenol, or 50% glycerin) via any known technique for medication dilution, including and without limitation by creating serial dilutions based on the animal’s weight. In one or more embodiments, the produced medication may then be mixed into a topical application medium, for example and without limitation, an oil-in-water cream, a water-in-oil cream, a gel, or an oil. Finally, the topical application compound may be applied regularly to the pinna of the animal’s ear or another location on the animal’s skin at which the topical application compound is unlikely to be rubbed or licked away. In one or more embodiments, one or more of the concentration and the dosage of the topical application compound may be increased at regular time intervals until a maintenance concentration and dosage are reached. Those skilled in the art may find it desirable to apply the topical application compound daily, though any practical time interval of administration falls within the scope of the invention. The present invention allows a small amount of allergen introduced dermally or Attorney Docket: 091665.0105 transdermally to the immune system of an animal via the topical application compound to desensitize the animal to the allergen. In this way, an animal’s immunologic response to an allergen may be lessened over time until the animal is no longer allergic to the allergen.

[0020] The terms "‘topical application compound.” “topical application medium.” and the plural forms of those terms are used herein as umbrella terms for pharmaceutical bases by which allergens may be applied to the skin of an animal for absorption to the immune systems, including and without limitation all forms of creams, gels, and oils whether administered dermally or transdermally; the terms “topical application compound,” “topical application medium,” and the plural forms of those terms should be understood to include combinations comprising (1) one or more media and one or more allergen and (2) one or more media without an allergen yet inserted. The terms “dog” and “dogs” are used herein to mean any one or more canines owned, domesticated, or cared for by one or more humans. Similarly, the terms “cat” and “cats” are used herein to mean any one or more felines owned, domesticated, or cared for by one or more humans. The terms “owner” and "owners" are used herein to mean one or more ow ners of one or more animals. The term “transdennal” and derivatives thereof is used herein to mean administration to one or more pinnae of one or more animal’s ears. The terms “dermal,” “topical.” and derivatives thereof are used herein to mean administration to one or more animal’s skin; these terms are broader than “transdermal,” and they apply to application to the skin of the pinna of the ear as w ell as any other location on the skin.

[0021] In one or more aspects of the present disclosure, a veterinarian, veterinary technician, researcher, or owner may utilize an information handling system to control one or more operations associated with the process of producing or administering one or more dermal or transdermal immunotherapy topical application compounds. An information handling system may include any system or mechanism by which information may be processed, stored, transmitted, copied, received, or otherwise handled. Examples of information handling systems include computers, smart devices, processors, network storage systems, or any other by which information may be handled. The information handling system may include one or more of a hard drive, random access memory (RAM), a processing system (for example and without limitation, a central processing unit (CPU)), read-only memory (ROM), a disk drive, a mechanism for communicating with external devices (including and without limitation via a the Internet, an intranet, or a local connection), and an input and / or output device (including and without limitation a mouse, a keyboard, or a display), including multiples of the preceding Attorney Docket: 091665.0105 list (for example and without limitation, multiple input devices). In one or more embodiments, the information handling system may connect to external devices via one or more of a wired or wireless connection. In one or more embodiments, the information handling system may send one or more signals to control one or more pieces of hardware (for example and without limitation, a dispenser of emulsion cream).

[0022] Illustrative embodiments of the present disclosure are described in detail herein. In the interest of clarity', not all features of an actual implementation may be described in this specification. It will of course be appreciated that in the development of any such actual embodiment, numerous implementation-specific decisions may be made to achieve the specific implementation goals, which may vary from one implementation to another. Moreover, it will be appreciated that such a development effort might be complex and time-consuming but would nevertheless be a routine undertaking for those of ordinary skill in the art having the benefit of the present disclosure.

[0023] The present disclosure discloses several embodiments specific to atopic dermatitis. These embodiments are by way of example and not limitation. One skilled in the art and with the benefit of the present disclosure would understand that the disclosed systems and methods may be practiced to treat other indications. For example, and without limitation, the disclosed systems and methods may be practiced to treat and / or prevent any one or more of canine asthma, feline asthma, and feline atopic skin syndrome (“FAAS”).

[0024] Throughout this disclosure, a reference numeral followed by an alphabetical character refers to a specific instance of an element and the reference numeral alone refers to the element generically or collectively. Thus, as an example (not shown in the drawings), widget “la” refers to an instance of a widget class, which may be referred to collectively as widgets “1” and any one of which may be referred to generically as a widget “1”. In the figures and the description, like numerals are intended to represent like elements.

[0025] To facilitate a better understanding of the present disclosure, the following examples of certain embodiments are given. In no way should the following examples be read to limit, or define, the scope of the disclosure. Embodiments of the present disclosure may be applicable to any system, process, or mechanism for one or more of diluting an allergen into a diluent, placing the diluent / allergen mix into a topical application medium, and applying the Attorney Docket: 091665.0105 topical application compound dermally or transdermally to an animal. Embodiments described below with respect to one implementation are not intended to be limiting.

[0026] FIG. 1 depicts an exemplary' illustration of an immunotherapy cream being applied transdermally to the pinna of a dog’s ear, according to one or more aspects of the present disclosure. Though a dog’s ear is depicted, FIG. 1 should be understood to apply to the ears of any animal. Further, FIG. 1 should be understood to apply to the ears or any other suitable location on an animal’s skin for administration of an immunotherapy cream. Additionally, though a cream is depicted in FIG. 1, embodiments using any form of one or more topical application compounds (including and without limitation any cream, gel, or oil) are well within the scope of this disclosure.

[0027] In one or more embodiments, a topical application compound 103 (for example and without limitation, an emulsion cream mixed with an allergen) may be applied via an emulsion pen 101 transdermally to the pinna 105 of an animal’s ear. In one or more embodiments, the topical application compound 103 may be applied by one or more of an emulsion pen 101, a micro-pen, a syringe, by hand, or via any other method of application. In one or more embodiments, the topical application compound 103 may be applied dermally to a suitable location. A location is suitable if (1) it is probable that the topical application compound will be absorbed into the skin (for example and without limitation, if the area of the skin is not unduly obscured by hair or fur) and (2) it is unlikely that the animal will rub. lick, or otherwise remove the topical application compound from the skin before the allergen has been absorbed into the immune system. An Elizabethan collar — that is, a cone-shaped, cylinder-shaped, or other configuration of a blocking material (including and without limitation plastic, fabric, cardboard, cloth, and fiber) used to surround one or more of an animal’s head or neck to prevent the animal from licking, rubbing, or biting a part of its body — may be used to prevent the animal from rubbing, licking, or otherwise removing the topical application compound from the skin before the allergen has been absorbed into the immune system. In one or more embodiments, the topical application compound 103 may be applied to the pinna of the ear or a semi-hairless portion of the abdomen — this list is not meant to be exhaustive, and any suitable location is within the scope of this disclosure. In one or more embodiments, it may be desirable to alternate the application location, for example and without limitation, by administering a first dose to an animal’s right pinna, a second dose to the animal’s left pinna, and subsequent doses to alternating pinnae. Attorney Docket: 091665.0105

[0028] In one or more embodiments, a micro-pen or emulsion pen 101 may be used to administer the topical application compound 103 by rotating the pen 101 until it clicks. Each click, the pen 101 may dispense a quantity of topical application compound 103, for example and without limitation, 0.05 milliliters (mL). In one or more embodiments, the topical application compound 103 may then be gently rubbed into the application site 105. This rubbing may continue for any period sufficient to allow for absorption of the topical application compound 103, for example and without limitation, for five to ten seconds. In some embodiments, a veterinarian, veterinary' technician, researcher, or owner may administer the topical application compound 103. In one or more embodiments, it may be desirable to administer the topical application compound regularly, for example and without limitation, once per day. Further, it may be desirable to steadily increase one or more of the concentration or quantity' of the topical application compound 103 until a maintenance concentration is reached.

[0029] The present invention allows a small amount of allergen introduced through the skin to the immune system of the animal via the topical application compound 103 to desensitize the animal to the allergen. In this way, an animal’s immunologic response to an allergen may be lessened over time until the animal is no longer allergic to the allergen. The invention may be used to treat one or more allergic conditions, for example and without limitation, atopic dermatitis.

[0030] FIG. 2 depicts an exemplary diagram of a method for creating serial dilutions of an immunotherapy cream, according to one or more aspects of the present disclosure. Though a cream is depicted in FIG. 2, embodiments using any form of one or more topical application compounds (including and without limitation any cream, gel, or oil) are well within the scope of this disclosure. FIG. 2 depicts three dilutions 201, 203, and 205; however, those skilled in the art will understand that any number of dilutions may be used without departing from the scope of the present disclosure. In one or more embodiments, a first dilution 201 may be formed via a mixture of an allergen and a diluent. The allergen should be the allergen to which an animal is allergic. The diluent may be any known diluent, including and without limitation HSA, sterile water, sterile water with phenol. 50% glycerin, or any combination therein. In one or more embodiments, a portion of the first dilution 201 may be transferred 207 to begin creation of a second dilution 203. Additional diluent may be added to the second dilution 203 to achieve a less concentrated dilution. In one or more embodiments, a portion of Attorney Docket: 091665.0105 the second dilution 203 may then be transferred 209 to begin creation of a third dilution 205. Additional diluent may be added to the third dilution 205 to achieve an even less concentrated dilution. The dilutions may be added to one or more topical application media (including and without limitation one or more of emulsion cream bases, gel bases, or oil bases) to form an immunotherapy topical application compound via any method by which a dilution may be added to a topical application medium, for example and without limitation, syringe-to-syringe, an electronic method such as an electric mortar and pestle (commonly known in the art as an “EMP’ ), or by hand with a traditional mortar and pestle or ointment slab. Tw o example dilution series are provided below. In the following examples, note that multiple allergens may be used simultaneously and may act as diluent with respect to other allergens; for example and without limitation, if the requisite ratio were 0. 1 mL of an allergen with 1.9 mL of a diluent, 12 allergens of 0. 1 mL each could be mixed with 0.8 mL of a diluent; in this w a . each allergen w oul d make up 1 / 20 of the total compound. Though the below examples only discuss mixing one allergen at a time, compounds using multiple allergens simultaneously fall well within the scope of this disclosure, including compounds with a sufficient number of distinct allergens such that no traditional diluent is needed (in the prior example, a compound w ith tw enty different allergens would not need a traditional diluent). Further, though the below examples discuss creams, note that similar embodiments using one or more creams, gels, or oils fall within the scope of the present disclosure.

[0031] In one or more embodiments, 0. 1 mL of an allergen may be mixed w ith 1.9 mL of a diluent to form a first dilution 201 totaling 2 mL and bearing a ratio of one-part allergen per twenty parts of the first dilution 201. In one or more embodiments, 0.4 mL may be transferred 207 from the first dilution 201 to begin creation of the second dilution 203. 1 .6 mL of diluent may be added to the transferred 0.4 mL to form a second dilution 203 totaling 2 mL and bearing a ratio of one-part allergen per one hundred parts of the second dilution 203. In one or more embodiments, 0.4 mL may be transferred 209 from the second dilution 203 to begin creation of the third dilution 205. 1.6 mL of diluent may be added to the transferred 0.4 mL to form a third dilution 205 totaling 2 mL and bearing a ratio of one-part allergen per five hundred parts of the dilution. In one or more embodiments, 0.8 mL of the third dilution 205 may be mixed with 3.2 mL of cream to form an immunotherapy cream for application during a first month; this exemplary immunotherapy cream would have a total volume of 4 mL and a ratio of one part allergen per 2,500 parts immunotherapy cream. In one or more embodiments, Attorney Docket: 091665.0105 immunotherapy cream for application during a second month; this exemplary immunotherapy cream would have a total volume of 4 mL and a ratio of one part allergen per five hundred parts immunotherapy cream. In one or more embodiments, 0.8 mL of the first dilution 201 may be mixed with 3.2 mL of cream to form an immunotherapy cream for application during a third month; this exemplary immunotherapy cream would have a total volume of 4 mL and a ratio of one part allergen per one hundred parts immunotherapy cream. In one or more embodiments, a maintenance cream may be formed by7combining 2mL of the first dilution 201 with 8mL of the cream for application following the third month; this exemplary7immunotherapy cream would have a total volume of lOmL and a ratio of one part allergen per one hundred parts immunotherapy cream. In one or more embodiments, any dilution that remains after forming a cream may be saved for the next time cream is formed. The above exemplary dilution series may be suitable for animals weighing equal to or more than twenty7pounds. Those skilled in the art will understand that the above example is purely exemplary7and that the present invention may be practiced via any concentration and / or quantity of diluent, allergen, and cream.

[0032] As another example, in one or more embodiments, 0.05 mL of an allergen may be mixed with 4.95 mL of diluent to form a first dilution 201 totaling 5 mL and bearing a ratio of one-part allergen per one hundred parts of the first dilution 201. In one or more embodiments, 0.4 mL may be transferred 207 from the first dilution 201 to begin creation of the second dilution 203. 1.6 mL of diluent may be added to the transferred 0.4 mL to form a second dilution 203 totaling 2 mL and bearing a ratio of one-part allergen per five hundred parts of the second dilution 203. In one or more embodiments, 0.4 mL may be transferred 209 from the second dilution 203 to begin creation of the third dilution 205. 1 .6 mL of diluent may be added to the transferred 0.4 mL to form a third dilution 205 totaling 2 mL and bearing a ratio of one-part allergen per 2,500 parts of the dilution. In one or more embodiments, 0.8 mL of the third dilution 205 may be mixed with 3.2 mL of cream to form an immunotherapy7cream for application during a first month; this exemplary immunotherapy cream would have a total volume of 4 mL and a ratio of one part allergen per 12,500 parts immunotherapy cream. In one or more embodiments, 0.8 mL of the second dilution 203 may be mixed with 3.2 mL of cream to form an immunotherapy cream for application during a second month; this exemplary immunotherapy cream would have a total volume of 4 mL and a ratio of one part allergen per 2,500 parts immunotherapy cream. In one or more embodiments, 0.8 mL of the first dilution 201 may be mixed with 3.2 mL of cream to form an immunotherapy cream for application Attorney Docket: 091665.0105 during a third month; this exemplary immunotherapy cream would have a total volume of 4 mL and a ratio of one part allergen per five hundred parts immunotherapy cream. In one or more embodiments, a maintenance cream may be formed by combining 2mL of the first dilution 201 with 8mL of the cream for application following the third month; this exemplary immunotherapy cream would have a total volume of lOmL and a ratio of one part allergen per five hundred parts immunotherapy cream. In one or more embodiments, any dilution that remains after forming a cream may be saved for the next time cream is formed. The above exemplary dilution series may be suitable for animals weighing less than twenty' pounds. Those skilled in the art will understand that the above example is purely exemplary and that the present invention may be practiced via any concentration and / or quantity of diluent, allergen, and cream.

[0033] The topical application compound should be regularly delivered to the animal dermally or trans dermally. In one or more embodiments, the topical application compound may be applied daily. In one or more embodiments, a first topical application compound may be applied daily for a first month, a second topical application compound may be applied daily for a second month, a third topical application compound may be applied daily for a third month, and a maintenance topical application compound may be applied daily and perpetually after the third month. As the animal’s immune system becomes less sensitive to the allergen, more allergen can be safely applied to expedite desensitization. Thus, in many' embodiments, the first topical application compound may include the lowest total amount of allergen, the second topical application compound may include more allergen than the first topical application compound, the third topical application compound may include more allergen than the second topical application compound, and the maintenance topical application compound may include the most allergen. This is just one exemplary' schedule that may be used to practice the present invention; any suitable administration schedule may be used.

[0034] FIG. 3 depicts an exemplary flow diagram illustrating a method for creating and administering a dermal or transdermal immunotherapy cream, according to one or more aspects of the present disclosure. Though a cream is discussed in FIG. 3, embodiments using any form of one or more topical application compounds (including and without limitation any cream, gel, or oil) are well within the scope of this disclosure. In one or more embodiments, an animal care provider may receive an order 301. Non-limiting examples of animal care providers can include a veterinarian, a veterinary technician, a pharmacist, a pharmacy, an animal owner, a Attorney Docket: 091665.0105 veterinary product manufacturer, a veterinary product dispenser, or a veterinary product distributor. The order 301 may include one or more of the animal’s species, breed, weight, gender, one or more allergies, or one or more medical conditions. The information from the order 301 may be used to determine one or more suitable dosages 303 — that is, one or more combinations of suitable concentration and quantity of allergen to be applied to the animal per unit of time. In one or more embodiments, the dosage 303 may increase regularly over time until a maintenance dosage is reached 325 and 327. In one or more embodiments, it may be desirable to separate the dosage amounts 303 based on the animal’s weight. For example and without limitation, it may be desirable to have one predetermined sequence of dosages 303 for animals under twenty pounds and a different predetermined sequence of dosages 303 for animals over twenty pounds. In one or more embodiments, the dosages 303 may be created via a dilution series 305 and 307 as depicted in FIG. 2. FIG. 3 depicts two possible dilution series options 305 and 307, but those skilled in the art will understand that any number of dilution series options 305 and 307 or other dosage options 303 falls within the scope of the invention.

[0035] Once an appropriate dilution series 305 and 307 is created based on an animal’s order 301, a mixture of diluent and allergen may be mixed with a topical application medium such as a gel. oil. or cream 309 and 311. The topical application compound produced from the combination of the diluent, allergen, and topical application medium may then be applied to the animal’s skin or inner ear regularly 313 and 315. In one or more embodiments, a first dosage may be applied for a first month 313 and 315, a second dosage may be applied for a second month 317 and 319. a third dosage may be applied for a third month 321 and 323, and a maintenance dosage may be applied indefinitely 325 and 327 after the third month. Though FIG. 3 depicts three month-long dosages followed by a maintenance dose, the present invention may be administered via any number of successive dosages lasting any suitable length of time. In one or more embodiments, the topical application compound may be applied daily. In other embodiments, the topical application compound may be applied across other regular units of time, including and without limitation three times a day, twice a day, once every two days, or weekly.

[0036] FIG. 4 depicts a schematic diagram of an information handling system for use with the production and administration of medication, according to one or more aspects of the present disclosure. In one or more embodiments, the present invention may be practiced in combination with an information handling system, including one or more of a hard drive 405, Attorney Docket: 091665.0105 a GPU 407, a CPU 411. a connection system 415, a Basic Input / Output System (BIOS) 419, an Input / Output Controller Hub (ICH) 413, memory 417, RAM 403, ROM 409, an input element 401, an output element 421, and any multiple thereof (for example and without limitation, two hard drives). The input elements 401 may include one or more of a keyboard, a mouse, a touch screen, or other input elements. The output elements 421 may include one or more of a monitor, a speaker, or other output elements. The connection system 415 may be any means to connect to an external system, including and without limitation via the Internet, an intranet, or a local connection. Further, the connection system 409 may be wired, wireless, or any combination thereof. The CPU 411 may be any kind of processor, including and without limitation one or more microcontrollers, microprocessors, embedded processors, or digital signal processors.

[0037] In one or more embodiments, the disclosed systems and methods for producing and administering dermal and transdermal immunotherapy topical application compounds to animals may incorporate an information handling system in one or more ways. For example and without limitation, a hard drive 405 or other memory 417 storing device may store data about animal patients, for example and without limitation, one or more dosing schedules, prescriptions, orders, allergies, weights, species, breeds, genders, or medical conditions. In some embodiments, one or more processors 411 may use information from one or more input elements 401 to calculate one or more dosing schedules, including one or more dates, concentrations, or quantities for administration of immunotherapy topical application compounds. Data produced by one or more processors 411 may be communicated to a user via one or more output elements 421. In one or more embodiments, an information handling system may connect to external devices via one or more of a wired or wireless connection. In one or more embodiments, an information handling system may send one or more signals to control one or more pieces of hardware (for example and without limitation, a dispenser of topical application media). An information handling system may access information, including and without limitation one or more of animal patient records data or allergen data, from an outside source via one or more connection systems 415. Similarly, an information handling system may upload information, including and without limitation one or more of animal patient records data or allergen data, to an outside source via one or more connection systems 415.

[0038] The elements of FIG. 4 may be added, omitted, or changed in any combination without departing from the scope of the present disclosure. One or more elements of FIG. 4 Attorney Docket: 091665.0105 may be physical, logical, or any combination thereof. FIG. 4 depicts one exemplary information handling system; however, any information handling system including one or more elements from FIG. 4 may be used to practice the present invention.

[0039] The aforementioned techniques may be used to lessen an animal’s immunologic response to a variety of allergens. For example and as discussed herein, the topical application compound 103 may be used to reduce or substantially eliminate an animal’s immunologic response to plant-based allergens derived from one or more of Ash, Olive, Cedar, Cypress, Juniper, Cottonwood, Elm American. Eucalyptus, Maple, Box Elder, Melaleuca. Mesquite, Mulberry, Oak Mix, Alder, Birch, Pecan, Walnut, Palm, Pepper Tree, Pine, Queen Palm, Sycamore, Walnut, Willow, Orange, or Hazelnut trees. Further, the topical application compound 103 may be used to reduce or substantially eliminate an animal’s immunologic response to plant-based allergens derived from one or more of Cocklebur, Dog Fennel, Dock, Sorrel Mix, Golden Rod, Lamb’s Quarter. Marsh Elder, Mugwort, Dandelion, Sagebrush, English Plant, Nettle, Pigweed, Plantain, Ragweed, Russian Thistle, Scale, or Wing weeds. The topical application compound 103 may be used to reduce or substantially eliminate an animal’s immunologic response to plant-based allergens derived from one or more of Bahai, Bermuda, Johnson, Timothy. Brome, Fescue, Kentucky Bluegrass, Orchard, Red Top, Rye, or Sweet Vernal grasses. The topical application compound 103 may be used to reduce or substantially eliminate an animal’s immunologic response to mold or fungus-based allergens derived from one or more of Altemaria, Aspergillus, Cladosporium, Fusarium, Malassezia, Mucor, Penicillium, or Stemphylium solani. Further, the topical application compound 103 may be used to reduce or substantially eliminate an animal’s immunologic response to mite or insectbased allergens derived from one or more of Black Ant, Cockroach, House Fly, Dermatophagoides farinae, D. pteronyssinus, or Tyrophagus .

[0040] In some embodiments, the topical application compound 103 may be used to reduce or substantially eliminate an animal’s immunologic response to one or more tree-based allergens or shrub-based allergens. In some embodiments, the one or more tree-based allergens or shrub based allergens may include Acacia (Acacia spp.y, Alder, Hazel (Aims serrulata),' Alder, Red (Alnus rubray, Alder, White (Alnus rhombifolidy Ash, Arizona (Fraxinus velutina),' Ash, Oregon (Fraxinus latifolia)', Ash, Red / Green (Fraxinus pennsylvanicd),' Ash, White (Fraxinus americana),' Aspen (Populus tremuloidesy, Bayberry / Wax Myrtle (Myrica ceriferay, Beech, American (Fagus grandifolidy, Birch, Black / Sweet (Betula lento),' Birch, River (Betula Attorney Docket: 091665.0105 nigra) Birch, Spring (Betula occidentals); Birch. White (Betula populifolia); Box Elder (Acer negundo); Cedar, Mountain (Juniperus ashei); Cedar, Red (Juniperus virginiana); Cedar, Salt / Tamarisk (Tamarix gallica); Cottonwood, Black Populus balsamifera ssp. trichocarpa); Cottonwood, Eastern (Populus deltoides); Cottonwood, Fremont (Populus fremontii); Cottonwood, Western (Populus monilifera); Cypress, Arizona (Cupressus arizonica); Cypress, Bald (Taxodium distichum); Elm, American (Ulmus americana); Elm, Cedar / Fall Blooming (Ulmus crassifolia); Elm, Siberian (Ulmus pumila); Eucalyptus (Eucalyptus globulus); Hackberry (Celtis occidentalis); Hazelnut, American (Corylus americana); Hickory', Shagbark (Carya ovata); Hickory, Shellbark (Carya laciniosa); Hickory. White (Carya alba); Juniper, Oneseed (Juniperus monosperma); Juniper, Pinchot (Juniperus pinchotii); Juniper, Rocky Mountain (Juniperus scopulorum); Juniper, Utah (Juniperus osteosperma); Juniper, Western (Juniperus occidentalis); Locust Blossom, Black (Robinia pseudoacacia); Mango Blossom (Mangifera indica); Maple, Red (Acer rubrum); Maple, Silver / Soft (Acer saccharinum); Maple, Sugar / Hard (Acer saccharum); Melaleuca (Melaleuca quinquenervia); Mesquite (Prosopis glandulosa); Mulberry, Paper (Broussonetia papyrifera); Mulberry, Red (Morns rubra); Mulberry7, White (Morus alba); Oak, Arizona / Gambel (Quercus gambelii); Oak, Black (Quercus velutina); Oak, Bur (Quercus macrocarpa); Oak, California Black (Quercus kelloggii); Oak, California Live (Quercus agrifolia); Oak, California White (Quercus lobata); Oak, Post (Quercus stellata); Oak, Red (Quercus rubra); Oak, Virginia Live (Quercus virginiana); Oak, Water (Quercus nigra); Oak, Western White (Quercus garryana); Oak, White (Quercus alba); Olive (Olea europaea); Olive, Russian (Elaeagnus angustifolia); Orange Pollen (Citrus sinensis); Palm, Queen (Arecastrum romanzoffianum); Pecan (Carya illinoinensis); Pepper Tree (Schinus spp.); Pine, Australian (Beefwood) (Casuarina equisetifolia); Pine, Loblolly (Pinus taeda); Pine, Longleaf (Pinus palustris); Pine, Ponderosa (Pinus ponderosa); Pine, Virginia / Scrub (Pinus virginiana); Pine, Eastern White (Pinus strobus); Pine, Western White (Pinus monticola); Pine, Yellow (Pinus echinata); Poplar, Lombardy (Populus nigra); Poplar, White (Populus alba); Privet, Common (Ligustrum vulgare); Sweet Gum (Liquidambar styraciflua); Sycamore, American / Eastem (Platanus occidentalis); Sycamore, Western (Platanus racemosa); Walnut, Black (Juglans nigra); Walnut, California Black (Juglans californica); Walnut, English (Juglans regia); Willow, Arroyo (Salix lasiolepis); Willow, Black (Salix nigra), or a combination thereof.

[0041] In some embodiments, the topical application compound 103 may be used to reduce or substantially eliminate an animal’s immunologic response to one or more flower- Attorney Docket: 091665.0105 based allergens. In some embodiments, the one or more flower-based allergens may include Daisy Ox-Eye (Chrysanthemum leucanthemum),' Dandelion (Taraxacum officinale)', Sunflower (Helianthus annuus), or a combination thereof.

[0042] In some embodiments, the topical application compound 103 may be used to reduce or substantially eliminate an animal’s immunologic response to one or more plant-based allergens. In some embodiments, the one or more plant-based allergens may include Alfalfa (Medicago sativa); Mustard (Brassica spp.); Red Clover (Trifolium pratense); Sugar Beet (Beta vulgaris), or a combination thereof.

[0043] In some embodiments, the topical application compound 103 may be used to reduce or substantially eliminate an animal’s immunologic response to one or more weed-based allergens. In some embodiments, the one or more weed-based allergens may include Allscale (Atriplex polycar pay. Baccharis (Baccharis spp.): Burrobrush (Hymenoclea salsola): Careless Weed, Amaranth / Green (Amaranthus hybridus),' Cocklebur (Xanthium strumarium); Dock, Yellow / Curly (Rumex crispus): Dog Fennel (Eupatorium capillifolium)', Firebush / Kochia (Kochia scoparia)., Goldenrod (Solidago spp. ,' Hemp, Water (Amaranthus tuberculatus),' Iodine Bush (Allenrolfea occidentalism Lambs Quarter (Chenopodium album),' Lenscale / Quailbrush (Atriplex lentiformis)', Marsh Elder, Burweed / Giant Poverty (Iva xanthiifolia),' Marsh Elder, True / Rough (Iva annua).' Mugwort, Common (Artemisia vulgaris),' Mugwort, Darkleaved / Sagebrush, Prairie (Artemisia ludoviciana),' Nettle (Urtica dioica),' Palmer’s Amaranth (Amaranthus palmer i); Pigweed, Rough / Redroot (Amaranthus retroflexus).' Plantain, English (Plantago lanceolata),' Rabbit Bush (Ambrosia deltoidea) Ragweed, Desert (Ambrosia dumosa); Ragweed, False (Ambrosia acanthicarpa): Ragweed, Giant (Ambrosia trifida),' Ragweed, Short (Ambrosia artemisiifolia): Ragweed, Slender (Ambrosia confertiflora),' Ragweed, Southern (Ambrosia bidentata),' Ragweed, Western (Ambrosia psilostachya),' Russian Thistle (Salsola kali).' Sagebrush, Common (Artemisia tridentata),' Saltbush, Annual (Atriplex wrightii),' Sorrel, Sheep / Red (Rumex acetosella),' Wingscale (Atriplex canescens), or a combination thereof.

[0044] In some embodiments, the topical application compound 103 may be used to reduce or substantially eliminate an animal’s immunologic response to one or more grass-based allergens. In some embodiments, the one or more grass-based allergens may include Bahia Grass (Paspalum notatum),' Bermuda (Cynodon dactylon),' Brome Grass, Smooth (Bromus inermis)', Canarygrass (Phalaris arundinacea).' Com, Cultivated (Zea mays): Couch / Quack Attorney Docket: 091665.0105

[0045] Grass (Elytrigia repens); Johnson Grass (Sorghum halepense); Kentucky Blue / June (Poa pratensis); Meadow Fescue (Festuca elatior); Oats, Common / Cultivated (Avena sativa); Orchard (Dactylis glomerata); Redtop (Agrostis alba) Rye, Cultivated Secale cereale); Ryegrass, Giant Wild (Leymus condensates); Ryegrass, Italian (Lolium perenne ssp. multiflorum); Ryegrass, Perennial (Lolium perenne) Sweet Vernal (Anthoxanthum odoratum); Timothy (Phleum pratense); Velvetgrass (Holcus lanatus); Wheat, Cultivated (Triticum aestivum); Wheatgrass, Western (Elymus smithii)^ or a combination thereof.

[0046] In some embodiments, the topical application compound 103 may be used to reduce or substantially eliminate an animal’s immunologic response to one or more fungi-based allergens. In some embodiments, the one or more fungi-based allergens may include Acremonium strictum (Cephcdosporium acremonium ; Altemaria altemata (Alternaria tenuis) Aspergillus amstelodami (Aspergillus glaucus); Aspergillus flavus (Aspergillus flavus); Aspergillus fumigatus (Aspergillus fumigates); Aspergillus nidulans (Aspergillus nidulans); Aspergillus niger (Aspergillus niger); Aureobasidium pullulans (Pullularia pullulans); Bipolaris sorokiniana (Helminthosporium sativum); Botrytis cinerea (Botrytis cinerea); Candida albicans (Candida albicans); Chaetomium globosum (Chaetomium globosum); Cladosporium herbarum (Cladosporium herbarum); Cladosporium sphaerospermum (Hormodendrum hordei); Drechslera spicifera (Curvularia spicifera); Epicoccum nigrum (Epicoccum purpurascens); Epidermophyton floccosum (Epidermophyton floccosum); Fusarium moniliforme (Fusarium moniliforme); Fusarium solani (Fusarium solani); Geotrichum candidum (Geotrichum candidum); Gliocladium viride (Gliocladium deliquescens); Helminthosporium solani (Spondylocladium atrovirens); Malassezia pachydermatis (Malassezia pachydermatis); Mucor circinelloides f. circinelloides (Mucor mucedo); Mucor circinelloides f. lusitanicus (Mucor racemosus); Mucor plumbeus (Mucor plumbeus); Neurospora intermedia (Monilia sitophila); Paecilomyces variotii (Paecilomyces variotii); Penicillium chrysogenum (notatum) (Penicillium chrysogenum); Penicillium digitatum (Penicillium digitatum); Phoma betae (Phoma betae); Rhizopus oryzae (Rhizopus arrhizus); Rhizopus stolonifer (Rhizopus nigricans); Rhodotorula mucilaginosa var. mucilaginosa (Rhodotorula rubra); Saccharomyces cerevisiae (Saccharomyces cerevisiae); Stemphylium solani (Stemphylium solani); Trichoderma harzianum (Trichoderma viride); Trichophyton mentagrophytes (Trichophyton mentagrophytes); Trichophyton rubrum (Trichophyton rubrum); Trichothecium roseum (Cephalothecium roseumf or a combination thereof. Attorney Docket: 091665.0105

[0047] In some embodiments, the topical application compound 103 may be used to reduce or substantially eliminate an animal’s immunologic response to one or more epithelia- based allergens. In some embodiments, the one or more epithelia-based allergens may include Cat Epithelia (Fells catus (domesticus)),' Cattle Epithelia (Bos taurus),' Dog Epithelia (Canis familiaris).' Gerbil Epithelia (Meriones unguiculatus),' Goat Epithelia (Capra hircus),' Guinea Pig Epithelia (Cavia porcellus)', Hamster Epithelia (Mesocricetus auratus) Hog Epithelia (Sus scrofdy. Horse Epithelia (Equus caballus).' Human Dander; Mouse Epithelia (Mus musculus),' Rabbit Epithelia (Oryctolagus cuniculus),' Rat Epithelia (Rattus norvegicus),' Sheep Epithelia (Ovis aries), or a combination thereof.

[0048] In some embodiments, the topical application compound 103 may be used to reduce or substantially eliminate an animal’s immunologic response to one or more featherbased allergens. In some embodiments, the one or more feather-based allergens may include Canary Feathers (Serinus canaria)', Chicken Feathers (Gallus gallus).' Duck Feathers (Anas platyrhynchos)'. Parakeet Feathers (Psittacidaey or a combination thereof.

[0049] In some embodiments, the topical application compound 103 may be used to reduce or substantially eliminate an animal's immunologic response to one or more insectbased allergens. In some embodiments, the one or more insect-based allergens may include Ant, Black / Carpenter (Camponotus pennsylvanicus)', Ant, Fire (Solenopsis richteri),' Ant, Fire (Solenopsis Invicta),' Cockroach, American (Periplaneta americana),' Cockroach, German (Blattella germanica),' Culicoids (Culicodes spp.y, Deer Fly (Chrysops spp.y, Flea (Ctenocephalides spp.y. Horse Fly (Tabanus spp.y. House Fly (Musca domestica),' Mosquito (Culicidae)', Moth (Lepidopteray, Acarus siro; Blomia tropicalis; Dermatophagoides farina; Dermatophagoides pteronyssinus; Lepidoglyphus destructor; Tyrophagus putrescentiae, or a combination thereof.

[0050] In some embodiments, the topical application compound 103 may be used to reduce or substantially eliminate an animal’s immunologic response to one or more flowerbased allergens which may include Cotton Linters (Gossypium hirsutum).' Cottonseed (Gossypium hirsutum .' Flaxseed (Linum usitatissimum); Kapok Seed (Ceiba pentandray, Orris Root (Iris germanica var. florentina),' Pyrethrum (Chrysanthemum cinerariifolium),' Silk (Bombyx mori),' Tobacco Leaf (Nicotiana tabacum), or a combination thereof. Attorney Docket: 091665.0105

[0051] In some embodiments, the topical application compound 103 may include one or more manufactured allergens derived from any allergens disclosed herein. In some embodiments, the one or more manufactured allergens are derived from one or more plantbased allergens, one or more tree-based allergens, one or more shrub-based allergens, one or more flower-based allergens, one or more weed-based allergens, one or more grass-based allergens, one or more fungi-based allergens, one or more epithelia-based allergens, one or more feather-based allergens, one or more insect-based allergens, and combinations thereof. The one or more manufactured allergens may include one or more natural manufactured allergen extracts, one or more synthetic manufactured allergen extracts (e.g., recombinant allergens), or both. Natural manufactured allergen extracts (e.g., natural manufactured allergens) may include biological preparations derived from (e.g., directly from) natural sources such as plants, animals, molds, or insects. The natural manufactured allergen extracts may include a mixture of proteins and other components that elicit an allergic response in certain animals. In some embodiments, manufacturing the natural manufactured allergen extracts may involve collecting a source material (e.g., a portion of a plant, an animal, a mold, an insect, or combination thereol) and extracting allergenic proteins from the source material using one or more solvents. Manufacturing the manufactured allergens may further include purifying the extract to remove impurities and standardizing the extract to ensure consistent potency and efficacy.

[0052] In some embodiments, the synthetic manufactured allergen extracts may be artificially produced using biotechnological methods. For example, the synthetic manufactured allergen extracts may be generated by cloning genes that encode allergenic proteins and expressing the cloned genes in microbial systems, such as in bacteria or yeast. The resulting proteins may then be purified to ensure a high degree of purify and consistency across the synthetic manufactured allergen extracts. The synthetic manufactured allergen extracts may provide a more uniform and specific allergenic profile as compared to natural manufactured allergen extracts.

[0053] It should therefore be appreciated that the topical application compound 103 may be used to reduce or substantially eliminate an animal’s immunologic response to one or more manufactured allergens that may be used in immunotherapy. That is, the topical application compound 103 may include a quantify of one or more of the manufactured allergens, of one or more perennial allergens (e.g., such as those relating to molds, insects, or Attorney Docket: 091665.0105 both), or any other suitable allergen or combination of allergens, in accordance with the techniques discussed herein.

[0054] In some cases, it may be desirable to create, adjust, or otherwise customize the topical application compound 103 based on whether an animal exhibits an immunologic response to any one or combination of the aforementioned allergens. In this manner, the topical application compound 103 may be used to more effectively lessen an animal’s immunologic response to a particular allergen, or to a plurality of allergens, over time. As such, the topical application compound 103 may be administered to effectively reduce or substantially eliminate an animal’s allergy condition that may be triggered via exposure to any one or combination of the allergens set forth above.

[0055] In some embodiments, the topical application compound comprises about one or more allergens. In some embodiments, the topical application compound comprises about 1 or more, about 2 or more, about 3 or more, about 4 or more, about 5 or more, about 6 or more, about 7 or more, about 8 or more, about 9 or more, about 10 or more, about 11 or more, about 12 or more, about 13 or more, about 14 or more, or about 15 or more allergens. In some embodiments, the topical application compound comprises about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, or about 15 allergens. In some embodiments, the topical application compound comprises up to about 1, up to about 2, up to about 3, up to about 4, up to about 5, up to about 6, up to about 7, up to about 8, up to about 9, up to about 10, up to about 11, up to about 12, up to about 13, up to about 14, or up to about 15 allergens.

[0056] FIG. 5 is a flow diagram of an embodiment of a method 501 that may be used to treat the allergy condition of the animal. The allergy condition may be indicative of the animal experiencing a response (e.g.. an allergic response, an immunologic response) when exposed to one or more allergens. The method 501 may be used to determine whether and to what extent the animal is allergic to one or more allergens, and to create a topical application compound 103 tailored to treat the allergy condition. It should understood that the steps of the method 501 may be performed in any suitable order and are not limited to the exemplary order shown in FIG. 5. Moreover, it should be appreciated that certain steps of the method 501 may be omitted and that the method 501 may include additional steps in addition to those shown in FIG. 5. Attorney Docket: 091665.0105

[0057] The method 501 may begin with detecting that the animal has a response (e.g., an allergic response, an immunologic response) to one or more allergens that may induce an allergy condition in the animal, as indicated by block 503. For example, an animal care provider, such as a veterinarian, veterinary' technician, animal owner, or pharmacist, may determine whether the animal exhibits an immunologic response to exposure to one or more allergens. The immunologic response may be indicative of the animal being allergic to the one or more allergens (e.g., having an allergy condition). Based on this evaluation, the animal care provider may determine the allergen(s) for which the animal has an allergic condition. It should be understood that, in other embodiments, the animal care provider may implement any other suitable technique to determine the allergic condition of the animal. That is, the animal care provider may utilize any suitable method to determine the particular allergen or allergens that induce an allergic response in the animal in addition to, or in lieu of, analysis via the animal’s IgE.

[0058] In some embodiments, the animal care provider may determine whether the animal has the allergy condition based on evaluation of immunoglobin E (IgE) present within a sample of the animal’s blood. IgE is an antibody produced by the immune system of certain animals, such as dogs, cats, and other mammals, in response to exposure to an allergen or a combination of allergens. For example, when the animal is not or has not been exposed to the allergen, the animal may exhibit a normal IgE level that is relatively low (e.g., as measured via a blood sample taken from the animal). Upon exposure to an allergen, the animal's IgE level may rise and reach an elevated level, indicating an immunologic response to exposure to the allergen. An amount (e.g., a magnitude) of the elevated IgE level may be indicative of the animal ’s immunologic sensitivity to that particular allergen. As such, a relatively high IgE level may be indicative of the animal having a relatively strong immunologic reaction to a particular allergen, whereas a relatively low IgE level may be indicative of the animal having a relatively weak immunologic reaction to the allergen. An animal’s IgE level can therefore be used to determine the strength or severity of an animal’s immunologic response to one or more allergens. Indeed, the animal may exhibit specific IgE levels corresponding to each of a plurality7of allergens.

[0059] In some embodiments, the animal care provider may evaluate a blood sample of the animal to determine the animal’s specific IgE corresponding to each of one or more allergens. Based on a magnitude of the specific IgE, the animal care provider can determine Attorney Docket: 091665.0105 which allergen or allergens induced an immunologic response in the animal. That is, if the magnitude of the specific IgE corresponding to a particular allergen meets or exceeds a threshold level, the animal care provider may determine that the animal is allergic to the allergen, such that treatment via the topical application compound 103 is warranted. Conversely, if the magnitude of the specific IgE corresponding to the allergen is below the threshold level, the animal care provider may determine that the animal is not allergic or only mildly sensitive to the allergen, such that treatment via the topical application compound 103 is unwarranted. The animal care provider may evaluate the animal's specific IgE corresponding to about 1 or more, about 2 or more, about 3 or more, about 4 or more, about 5 or more, about 10 or more, about 15 or more, or about 20 or more individual allergens.

[0060] The method 501 includes creating serial dilutions for the topical application compound 103, as indicated by block 505. For example, in accordance with the techniques discussed above with respect to FIG. 2, the animal care provider may create a first dilution 201, a second dilution 203, and a third dilution 205, where each of the dilutions 201 , 203, and 205 may include a mixture of one or more allergens and a diluent (e.g., HSA, sterile water, sterile water with phenol, 50% glycerin, or any combination thereof). In some embodiments, the diluent may be omitted from the dilutions 201, 203, and 205. such as when there are a sufficient number of distinct allergens used in the combination such that the different allergens adequately dilute one another.

[0061] The animal care provider may include those allergens in the dilutions 201, 203, and 205 for which the animal is determined to be allergic using the techniques discussed in block 503, for example. In this way, the animal care provider may create a topical application compound 103 that most effectively treats the animal’s particular allergic condition. As a non- limiting example, the animal care provider may incorporate, in the dilutions 201, 203. and 205, any one or more of plant-based allergens derived from one or more of Ash, Olive. Cedar, Cypress, Juniper, Cottonwood, Elm American, Eucalyptus, Maple, Box Elder, Melaleuca, Mesquite, Mulberry, Oak Mix, Alder, Birch, Pecan, Walnut, Palm, Pepper Tree, Pine, Queen Palm, Sycamore, Walnut, Willow, Orange, or Hazelnut trees: any one or more of plant-based allergens derived from one or more of Cocklebur, Dog Fennel, Dock, Sorrel Mix, Golden Rod, Lamb’s Quarter, Marsh Elder, Mugwort, Dandelion, Sagebrush, English Plant, Nettle, Pigweed, Plantain, Ragweed, Russian Thistle, Scale, or Wing weeds; any one or more of plantbased allergens derived from one or more of Bahai, Bermuda, Johnson, Timothy, Brome, Attorney Docket: 091665.0105

[0062] Fescue. Kentucky Bluegrass. Orchard, Red Top, Rye, or Sweet V emal grasses; any one or more of mold or fungus-based allergens derived from one or more of Altemaria, Aspergillus, Cladosporium, Fusarium, Malassezia, Mucor, Penicillium, or Stemphylium solani; any one or more of mite or insect-based allergens derived from one or more of Black Ant, Cockroach, House Fly. D. farinae, D. pteronyssinus . or Tyrophagus,' any one or more of manufactured allergens disclosed herein that may be used in immunotherapy applications; any one or more of perennial allergens (e.g., such as those relating to molds, insects, or both); or any one or more of other suitable ty pes of allergens of interest.

[0063] As indicated by block 507, the method 501 includes combining the first dilution 201, the second dilution 203, and the third dilution 205 with a topical application medium (e.g., gel, oil, cream), in accordance with the techniques discussed above with reference to FIGS. 2 and 3, to create the topical application compound 103. As such, the animal care provider may create a first dose or dosage of the topical application compound 103 based on the third dilution 205, where the first dose includes a concentration of the one or more allergens (e g., as identified in block 503) that is relatively low. The animal care provider may create a second dose or dosage of the topical application compound 103 based on the second dilution 203, where the second dose includes a concentration of the one or more allergens (e.g.. as identified in block 503) that is moderate (e.g., as compared to the first dose of the topical application compound 103). Further, the animal care provider may create a third dose or dosage of the topical application compound 103 based on the first dilution 201, where the first dose includes a concentration of the one or more allergens (e.g.. as identified in block 503) that is relatively high (e.g., as compared to the second dose of the topical application compound 103). In accordance with the discussion above, it should be appreciated that a quantity or concentration of the one or more allergen in the first dose, a quantity7or concentration of the one or more allergen in the second dose, and a quantity' or concentration of the one or more allergen in the third dose may be determined based in part on one or more of a weight, a species, a breed, a gender, a preexisting condition, or an allergy status of the animal.

[0064] The method 501 includes applying the topical application compound 103 to the animal to treat the allergy condition, as indicated by block 509. In some embodiments, the animal care provider may administer the topical application compound 103 in accordance with the techniques set forth above. As anon-limiting example, the animal care provider may apply (e.g., dermally, transdermally) the first dose of the topical application compound 103 to the Attorney Docket: 091665.0105 animal for a first treatment interval (e.g., one month) and at a first treatment frequency (e.g., daily). The animal care provider may apply (e.g., dermally, transdermally) the second dose of the topical application compound 103 to the animal for a second treatment interval (e.g., one month) and at a second treatment frequency (e.g., daily). The second treatment interval may commence at the end of the first treatment interval. The animal care provider may apply (e.g., dermally, transdermally) the third dose of the topical application compound 103 to the animal for a third treatment interval (e.g., one month) and at a third treatment frequency (e.g., daily). The third treatment interval may commence at the end of the second treatment interval. In some embodiments, the animal care provider may continue to provide the animal with the third dose of the topical application compound 103 indefinitely (e.g.. once daily for a remainder of the animal’s life) as a maintenance dose.

[0065] In some embodiments, the animal care provider may adjust the first, second, or third treatment intervals, the first, second, or third treatment frequencies, or both, based on the type, quantity, or combination of allergens for which the animal is determined to be allergic in block 503. Additionally or alternatively, the animal care provider may adjust the first, second, or third treatment intervals, the first, second, or third treatment frequencies, or both, based on one or more specific IgE levels of the animal (e.g., as measured in block 503). As such, the animal care provider may customize a treatment schedule for the animal in a manner that enhances an effectiveness of the topical application compound 103 in reducing or eliminating the animal's immunologic response to a combination of one or more allergens. Non-limiting examples of animal care providers can include a veterinarian, a veterinary technician, a pharmacist, a pharmacy, an animal owner, a veterinary product manufacturer, a veterinary product dispenser, or a veterinary product distributor. In some embodiments, the animal care provider may determine the animal’s need for treatment and then create and fulfill an order of the topical application compound 103 in accordance with the techniques discussed herein. In certain embodiments, upon determining that the animal has a need for treatment via the topical application compound 103, the animal care provider request the order of the topical application compound 103 from a pharmacy, a distributor, or a manufacturer that creates and dispenses the topical application compound 103.

[0066] FIG. 6 is a flow diagram of an embodiment of a method 601 for determining an allergy status of an animal. The allergy status may indicate whether the animal has an allergic condition to one or more allergens, such that application of the topical application compound Attorney Docket: 091665.0105

[0067] 103 is warranted to treat the allergic condition. It should understood that the steps of the method 601 may be performed in any suitable order and are not limited to the exemplary order shown in FIG. 6. Moreover, it should be appreciated that certain steps of the method 601 may be omitted and that the method 601 may include additional steps in addition to those shown in FIG. 6.

[0068] As indicated by block 603, the method 601 may begin with determining the IgE level of an animal with respect to one or more allergens. For example, the animal care provider may determine specific IgE levels of the animal for one or more allergens of interest. The animal care provider may determine an immunologic sensitivity of the animal to each of the one or more allergens based on the specific IgE levels, as indicated by block 605. For example, in some embodiments, in response to a determination that the specific IgE level corresponding to a particular allergen meets or exceeds a threshold value, the animal care provider may determine that the animal has an immunologic sensitivity to that particular allergen. That is, the animal care provider may determine that the allergy status of the animal with respect to that allergen is “positive,” because the animal exhibits an allergic response to the allergen. Conversely, in response to a determination that the specific IgE level corresponding to the allergen is below the threshold value, the animal care provider may determine that the animal does not have or has only a mild immunologic sensitivity to that particular allergen. That is, the animal care provider may determine that the allergy status of the animal with respect to that allergen is “negative,” because the animal does not exhibit an allergic response to the allergen.

[0069] The animal care provider may repeat the aforementioned steps for each of a plurality of allergens of interest, such that the animal care provider may aggregate a first grouping of one or more allergens for which the animal has a “positive” allergy' status and a second grouping of one or more allergens for which the animal has a “negative” allergy status. In some embodiments, the animal care provider may create the topical application compound 103, in accordance with the aforementioned techniques, to include an amount of each of the allergens for which a “positive” allergy' status is determined. As such, the topic application compound 103 may be formulated to include only those allergens for which the animal is allergic. In this way, the topical application compound 103 may more effectively treat an animal’s allergy condition. That is, the topical application compound 103 may more effectively reduce the immunologic sensitivity of the animal to the one or more allergens that induce an allergic response in the animal. Attorney Docket: 091665.0105

[0070] In an example, allergy conditions of dogs were effectively treated using the topical application compound 103. Five dogs were identified as having a “positive” allergy status to D. Farinae, Ragweed, and Timothy. That is, each of the five dogs was identified as being allergic to D. Farinae. Ragweed, and Timothy using the aforementioned techniques. The specific IgE levels corresponding to D. Farinae, Ragweed, and Timothy were measured for each of the five dogs at the initiation of the study. These specific IgE levels will be referred to herein as the “baseline IgE” levels of the dogs.

[0071] The dogs were treated using the topical application compound 103, which was created via the techniques discussed above. Each of the doses included amounts of D. Farinae, Ragweed, and Timothy, collectively referred to below as the “study allergens,” which were mixed with a quantity7of topical application medium (e.g., cream). The first dose of the topical application compound 103 included a first quantity of the study allergens that was relatively low. The second dose of the topical application compound 103 used in the study included a second quantity of the study allergens that was relatively moderate (e.g., as compared to the first dose). The third dose of the topical application compound 103 used in the study included a third quantity of the study allergens that was relatively high (e.g., as compared to the second dose).

[0072] As such, a first concentration of the study allergens included in the first dose of the topical application compound 103 was less than a second concentration of the studyallergens included in the second dose of the topical application compound 103, and the second concentration of the study allergens included in the second dose of the topical application compound 103 was less than a third concentration of the study allergens included in the third dose of the topical application compound 103. The first dose of the topical application compound 103 included a ratio of one part allergen per 2,500 parts immunotherapy cream (e.g., topical application medium). The second dose of the topical application compound 103 included a ratio of one part allergen per 500 parts immunotherapy cream. The third dose of the topical application compound 103 included a ratio of one part allergen per 100 parts immunotherapy cream. In some cases, the first dose of the topical application compound 103 can include a ratio of one part allergen per 12,500 parts immunotherapy cream (e.g., topical application medium), the second dose of the topical application compound 103 can include a ratio of one part allergen per 2,500 parts immunotherapy cream, and the third dose of the topical Attorney Docket: 091665.0105 application compound 103 can include a ratio of one part allergen per 500 parts immunotherapy cream.

[0073] As part of the study, each dog was treated daily with the first dose of the topical application compound 103 for a period of one month. Upon conclusion of the first month treatment period, each dog was treated daily with the second dose of the topical application compound 103 for a period of one month. Upon conclusion of the second month treatment period, each dog was treated daily with the third dose of the topical application compound 103 for a period of one month. Upon conclusion of the third month treatment period, each dog was treated daily with the third dose of the topical application compound 103 for a three-month period. As such, the dogs received daily application of the topical application compound 103 for a period of six months as part of the study.

[0074] At the end of the six-month study period, the specific IgE levels corresponding to D. Farinae, Ragweed, and Timothy were again measured for each of the dogs using the aforementioned techniques. The specific IgE levels, as measured upon conclusion of the study (e.g., on the last day of the sixth month of the study), were compared to the corresponding baseline IgE levels for the dogs, as taken at the beginning of the study (e.g., on the first day of the first month of the study). 80 percent of the dogs tested showed a clinically positive response to the therapy regiment implement as part of the study (e.g., daily application of various doses of the topical application compound 103). For the 80 percent of dogs having the clinically positive response, the table below shows the average percentage reduction of the specific IgE levels for these dogs (e.g., as measured at the end of the study) as compared to the baseline IgE levels of the dogs (e.g., as measured at commencement of the study).

[0075] TABLE 1 Attorney Docket: 091665.0105

[0076] The dogs experienced a significant average reduction in specific IgE for each of D. Farinae, Ragweed, and Timothy (Table 1). As such, the study demonstrates that the topical application compound 103 effectively reduces IgE levels corresponding to D. Farinae, Ragweed, and Timothy allergens. These findings suggest a clinically meaningful improvement in allergic symptoms for the tested dogs, indicating the overall efficacy of the treatment across the allergens tested in the study.

[0077] An embodiment of the present disclosure is a method for treating an allergy condition of an animal, comprising: detecting that the animal has the allergy condition; determining a first quantity of a topical application medium and a first quantity of an allergen based at least in part on one or more attributes of the animal; providing a first topical application compound, the first topical application compound comprising the first quantity of the allergen and the first quantity of the topical application medium; and applying the first topical application compound to one or more ears of the animal one or more times to treat the allergy condition.

[0078] In one or more embodiments, the first topical application compound may be applied to one or more pinnae of one or more ears. In one or more embodiments, the animal may be a dog or a cat. In one or more embodiments, the attributes of the animal may comprise one or more of a weight, a species, a breed, a gender, a preexisting condition, or an allergy diagnosis of the animal. In one or more embodiments, the allergy' condition may comprise atopic dermatitis. In one or more embodiments, the first quantity of the topical application medium and the first quantity of the allergen may be determined at least in part based on information from an information handling system. In one or more embodiments, the first topical application compound may be applied to one or more ears of the animal by: inserting Attorney Docket: 091665.0105 at least the first topical application compound into an emulsion pen; holding an ejecting end of the emulsion pen near or against the one or more ears of the animal; actuating the emulsion pen to emit the first topical application compound from the ejecting end; and rubbing the first topical application compound against the one or more ears of the animal. In one or more embodiments, the method for treating an allergy condition of an animal may further comprise: determining a second quantity of the topical application medium and a second quantity of the allergen; providing a second topical application compound comprising the second quantity of the topical application medium and the second quantity of the allergen; and applying the second topical application compound to one or more ears of the animal one or more times. In one or more embodiments, the first topical application compound may be applied at regular time intervals for a first predetermined period of time, and the second topical application compound may subsequently be applied at the regular time intervals for a second predetermined period of time. In one or more embodiments, the second quantity of the allergen may be greater than the first quantity of the allergen.

[0079] An embodiment of the present disclosure is a method for treating an allergy condition of an animal, comprising: detecting that the animal has the allergy condition; determining a first quantity of a topical application medium and a first quantity of an allergen based at least in part on one or more attributes of the animal; providing a first topical application compound comprising the first quantity of the topical application medium and the first quantity of the allergen; affixing an Elizabethan collar to a neck or a head of the animal; and applying the first topical application compound to one or more locations on the animal's skin one or more times.

[0080] In one or more embodiments, the topical application compound may be applied to the one or more locations on the animal’s skin by inserting at least the first topical application compound into an emulsion pen; holding an ejecting end of the emulsion pen near or against the one or more locations on the animal’s skin; actuating the emulsion pen to emit the first topical application compound out of the ejecting end; and rubbing the first topical application compound against the animal’s skin. In one or more embodiments, the method for treating an allergy condition of an animal may further comprise determining a second quantity of the topical application medium and a second quantity of the allergen; providing a second topical application compound, comprising the second quantity of the topical application medium and the second quantity of the allergen; and applying the second topical application compound to Attorney Docket: 091665.0105 one or more locations on the animal’s skin one or more times. In one or more embodiments, the first topical application compound may be applied at regular intervals for a first predetermined period of time, and the second topical application compound may subsequently be applied at the regular time intervals for a second predetermined period of time.

[0081] An embodiment of the present disclosure is a system, comprising: a topical application compound capable of treating an allergy condition of an animal via dermal or transdermal application of the topical application compound comprising an allergen and a topical application medium; a cylindrical body holding the topical application compound; and an opening disposed upon an end of the cylindrical body through which the topical application compound may exit the ej ection tube.

[0082] In one or more embodiments, the topical application compound may further comprise a diluent. In one or more embodiments, the ejection tube may be an emulsion pen. a micro-pen, or a syringe. In one or more embodiments, one or more of a quantity of the diluent, a quantity of the allergen, and a quantity' of the topical application medium may be determined based on one or more of a weight, a species, a breed, a gender, a preexisting condition, or an allergy diagnosis of the animal. In one or more embodiments, the diluent may comprise one or more of human serum albumin, sterile water, sterile water with phenol, or 50% glycerin. In one or more embodiments, the system may further comprise an information handling system, the information handling system comprising: an output system comprising one or more of a screen or a speaker; a non-transitory computer readable medium for storing instructions; and a processor that executes the instructions from the non-transitory computer readable medium, causing the processor to: determine a quantity of the topical application medium and a quantity of the allergen based at least in part on one or more attributes of an animal; and cause the output system to provide information about one or more of the quantity of the topical application medium and the quantity of the allergen to a user.

[0083] An embodiment of the present disclosure is a method for treating an allergy condition of an animal, comprising: detecting that the animal has one or more allergy condition, wherein the one or more allergy condition comprises one or more plant-based allergen, one or more mold or fungus-based allergen, one or more mite or insect-based allergen, or a combination thereof; determining a first quantity of a topical application medium and a first quantity of the one or more allergens based at least in part on one or more attributes of the animal; providing a first topical application compound, the first topical application compound Attorney Docket: 091665.0105 comprising: the first quantity’ of the one or more allergens; and the first quantity of the topical application medium; and applying the first topical application compound to the animal to treat the allergy’ condition.

[0084] In one or more embodiments, the one or more plant-based allergen may be selected from the group consisting of Ash, Olive, Cedar, Cypress, Juniper, Cottonwood, Elm American, Eucalyptus, Maple, Box Elder, Melaleuca, Mesquite, Mulberry', Oak Mix, Alder, Birch, Pecan, Walnut, Palm, Pepper Tree, Pine, Queen Palm, Sycamore, Walnut, Willow, Orange, Hazelnut, Cocklebur, Dog Fennel, Dock, Sorrel Mix, Golden Rod, Lamb’s Quarter, Marsh Elder, Mugwort, Dandelion, Sagebrush, English Plant, Nettle, Pigweed, Plantain, Ragweed, Russian Thistle, Scale, Wing, Bahai grass, Bermuda grass, Johnson grass, Timothy grass, Brome grass, Fescue grass, Kentucky Bluegrass, Orchard grass, Red Top grass, Rye grass, Sweet Vernal grass, or combinations thereof. In one or more embodiments, the one or more mold or fungus-based allergen may be selected from the group consisting of Altemaria, Aspergillus, Cladosporium, Fusarium, Malassezia, Mucor, Penicillium, Stemphylium solani, or combinations thereof. In one or more embodiments, the one or more mite or insect-based allergen may be selected from the group consisting of Black Ant, Cockroach, House Fly, Dermatophagoides farinae, D. pteronyssinus, Tyrophagus, or combinations thereof. In one or more embodiments, the one or more allergy condition comprises one or more manufactured allergens. In one or more embodiments, the method may further comprise determining a second quantity’ of the topical application medium and a second quantity’ of the one or more allergens; providing a second topical application compound, comprising: the second quantity of the topical application medium; and the second quantity of the one or more allergens; and applying the second topical application compound to the animal to treat the allergy condition. In one or more embodiments, the method may further comprise determining a third quantity of the topical application medium and a third quantity of the one or more allergens; providing a third topical application compound, comprising: the third quantity of the topical application medium; and the third quantity of the one or more allergens; and applying the third topical application compound to the animal to treat the allergy7condition. In one or more embodiments, applying the first topical application compound may comprise administering the first topical application compound dermally by applying the first topical application compound to one or more portions of skin of the animal. In one or more embodiments, applying the first topical application compound may comprise administering the first topical application compound transdermally by applying the first topical application compound to one or more pinnae of one Attorney Docket: 091665.0105 or more ears of the animal. In one or more embodiments, the method further comprises detecting that the animal has a response to the one or more allergens based on an immunoglobin E (IgE) level of the animal. In one or more embodiments, the method further comprises determining a treatment interval of the first topical application compound, a treatment frequency of the first topical application compound, or both, based on the IgE level. In one or more embodiments, the one or more attributes of the animal may comprise one or more of a weight, a species, a breed, a gender, a preexisting condition, or an allergy diagnosis of the animal. In some embodiments, the one or more allergens comprises Timothy grass. In some embodiments, the one or more allergens comprises Ragweed. In some embodiments, the one or more allergens comprises D. Farinae. In one or more embodiments, the one or more allergens may comprise at least one of Timothy grass, Ragweed, and D. Farinae. In one or more embodiments, the one or more allergens may comprise at least two of Timothy grass, Ragweed, and D. Farinae. In some embodiments, the one or more allergens comprises Timothy grass and Ragweed. In some embodiments, the one or more allergens comprises Ragweed and D. Farinae. In some embodiments, the one or more allergens comprises Timothy grass and D. Farinae. In one or more embodiments, the one or more allergens may comprise Timothy grass, Ragweed, and D. Farinae.

[0085] An embodiment of the present disclosure is a method for determining an allergy status of an animal, comprising: determining an immunoglobin E (IgE) level of the animal, wherein the IgE level corresponds to one or more allergens that induce an allergy’ condition in the animal; determining an immunologic sensitivity of the animal to the one or more allergens based on the IgE level; and determining that the allergy’ status of the animal is positive or negative based on the immunologic sensitivity’ of the animal.

[0086] In one or more embodiments, the method may further comprise applying a topical application compound to the animal when the allergy status of the animal is positive, wherein the topical application compound is formulated to reduce the immunologic sensitivity of the animal to the one or more allergens. In one or more embodiments, the topical application compound may comprise one or more plant-based allergen selected from the group consisting of Ash. Olive, Cedar, Cypress, Juniper, Cottonwood, Elm American, Eucalyptus, Maple, Box Elder, Melaleuca, Mesquite, Mulberry, Oak Mix, Alder, Birch, Pecan, Walnut, Palm, Pepper Tree, Pine, Queen Palm, Sycamore, Walnut, Willow, Orange, Hazelnut, Cocklebur, Dog Fennel, Dock, Sorrel Mix, Golden Rod, Lamb’s Quarter, Marsh Elder, Mugwort, Dandelion, Attorney Docket: 091665.0105

[0087] Sagebrush. English Plant, Nettle, Pigweed, Plantain, Ragweed. Russian Thistle, Scale, Wing, Bahai grass, Bermuda grass, Johnson grass, Timothy grass, Brome grass, Fescue grass, Kentucky Bluegrass, Orchard grass, Red Top grass, Rye grass, Sweet Vernal grass, or combinations thereof. In one or more embodiments, the topical application compound may comprise one or more mold or fungus-based allergen selected from the group consisting of Altemaria, Aspergillus, Cladosporium, Fusarium, Malassezia, Mucor, Penicillium, Stemphylium solani, or combinations thereof. In one or more embodiments, the topical application compound may comprise one or more mite or insect-based allergen selected from the group consisting of Black Ant, Cockroach, House Fly, D. farinae, D. pteronyssinus , Tyrophagus, or combinations thereof. In one or more embodiments, the topical application compound comprises one or more manufactured allergens. In one or more embodiments, the method may further comprise: determining a first dose of the topical application compound based on one or more of a weight, a species, a breed, a gender, a preexisting condition, or the allergy status of the animal; and applying the first dose of the topical application compound when the allergy status of the animal is positive. In one or more embodiments, the method may further comprise: applying the first dose of the topical application compound to the animal for a first treatment interval; and applying a second dose of the topical application compound to the animal for a second treatment interval occurring after the first treatment interval, wherein a first concentration of the first dose of the topical application compound is less than a second concentration of the second dose of the topical application compound. In one or more embodiments, the method may further comprise: applying a third dose of the topical application compound to the animal for a third treatment interval occurring after the second treatment interval, wherein the second concentration of the second dose of the topical application compound is less than a third concentration of the third dose of the topical application compound.

[0088] While the present disclosure has been described in connection with presently preferred embodiments, it will be understood by those skilled in the art that it is not intended to limit the disclosure to those embodiments. It is therefore contemplated that various alternative embodiments and modifications may be made to the disclosed embodiments without departing from the spirit and scope of the disclosure defined by the appended claims and equivalents thereof. In particular, with regard to the methods disclosed, one or more steps may not be required in all embodiments of the methods and the steps disclosed in the methods may be performed in a different order than was described. Furthermore, no limitations are Attorney Docket: 091665.0105 intended to the details of construction or design herein shown, other than as described in the claims below. It is therefore evident that the particular illustrative embodiments disclosed above may be altered or modified and all such variations are considered within the scope and spirit of the present disclosure. In particular, every' range of values (for example, “from about a to about b,” or, equivalently, “from approximately a to b,” or, equivalently, “from approximately a-b”) disclosed herein is to be understood as referring to the power set (the set of all subsets) of the respective range of values. Furthermore, the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “has” and “have”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are to be understood as inclusive or open-ended and do not exclude additional, unrecited elements or method steps. The word “some” is to be understood as meaning “one or more.” The terms “topical application compound,” “topical application medium,” and the plural forms of those terms are used herein as umbrella terms for pharmaceutical bases by which allergens may be applied to the skin of an animal for absorption to the immune systems, including and without limitation all forms of creams, gels, and oils whether administered dermally or transdermally; the terms “topical application compound,” “topical application medium,” and the plural forms of those terms should be understood to include combinations comprising (1) one or more media and one or more allergen and (2) one or more media without an allergen yet inserted. Further, the terms “topical application compound, “topical application medium,” and the plural forms of those terms include homogenous and non-homogenous media. The terms “dog” and “dogs” are used herein to mean any one or more canines owned, domesticated, or cared for by one or more humans. Similarly, the terms “cat” and “cats” are used herein to mean any one or more felines owned, domesticated, or cared for by one or more humans. The term “coupled” should be understood to include any connection betw een two things, including and without limitation a physical connection (including and without limitation a wired connection), a non-physical connection (including and without limitation a wireless connection), or any combination thereof. The terms in the claims have their plain, ordinary meaning unless otherwise explicitly and clearly defined by the patentee.

Claims

Attorney Docket: 091663.0105CLAIMSWhat is claimed is:

1. A method for treating an allergy condition of an animal, comprising: detecting that the animal has one or more allergy condition, wherein the one or more allergy condition comprises one or more plant-based allergen, one or more mold or fungus-based allergen, one or more mite or insect-based allergen, or a combination thereof; determining a first quantity of a topical application medium and a first quantity of the one or more allergens based at least in part on one or more attributes of the animal; providing a first topical application compound, the first topical application compound comprising: a) the first quantity of the one or more allergens; and b) the first quantity of the topical application medium; and applying the first topical application compound to the animal to treat the allergy condition.

2. The method of claim 1, wherein the one or more plant-based allergen is selected from the group consisting of Ash, Olive, Cedar, Cypress, Juniper, Cottonwood, Elm American, Eucalyptus, Maple, Box Elder, Melaleuca, Mesquite, Mulberry, Oak Mix, Alder, Birch, Pecan, Walnut, Palm, Pepper Tree, Pine, Queen Palm, Sycamore, Walnut, Willow, Orange, Hazelnut, Cocklebur, Dog Fennel, Dock, Sorrel Mix, Golden Rod, Lamb’s Quarter, Marsh Elder, Mugwort, Dandelion, Sagebrush, English Plant, Nettle, Pigweed, Plantain, Ragweed, Russian Thistle, Scale, Wing, Bahai grass, Bermuda grass, Johnson grass, Timothy grass, Brome grass, Fescue grass, Kentucky Bluegrass, Orchard grass, Red Top grass, Rye grass, Sweet Vernal grass, or combinations thereof.

3. The method of claim 1, wherein the one or more mold or fungus-based allergen is selected from the group consisting of Altemaria, Aspergillus, Cladosporium, Fusarium, Malassezia, Mucor, Penicillium, Stemphylium solani, or combinations thereof.

4. The method of claim 1, wherein the one or more mite or insect-based allergen is selected from the group consisting of Black Ant, Cockroach, House Fly, Dermatophagoides farinae D. pteronyssinus, Tyrophagus, or combinations thereof.Attorney Docket: 091663.01055. The method of claim 1, wherein the one or more allergy condition comprises one or more manufactured allergen.

6. The method of claim 1, further comprising: determining a second quantity of the topical application medium and a second quantity of the one or more allergens; providing a second topical application compound, comprising: a) the second quantity of the topical application medium; and b) the second quantity of the one or more allergens; and applying the second topical application compound to the animal to treat the allergy condition.

7. The method of claim 6, further comprising: determining a third quantity of the topical application medium and a third quantity of the one or more allergens; providing a third topical application compound, comprising: a) the third quantity of the topical application medium; and b) the third quantity of the one or more allergens; and applying the third topical application compound to the animal to treat the allergy condition.

8. The method of claim 1, wherein applying the first topical application compound comprises administering the first topical application compound dermally by applying the first topical application compound to one or more portions of skin of the animal.

9. The method of claim 1, wherein applying the first topical application compound comprises administering the first topical application compound transdermally by applying the first topical application compound to one or more pinnae of one or more ears of the animal.

10. The method of claim 1, further comprising detecting that the animal has a response to the one or more allergens based on an immunoglobin E (IgE) level of the animal.Attorney Docket: 091663.010511. The method of claim 10, further comprising determining a treatment interval of the first topical application compound, a treatment frequency of the first topical application compound, or both, based on the IgE level.

12. The method of claim 1, wherein the one or more attributes of the animal comprise one or more of a weight, a species, a breed, a gender, a preexisting condition, or an allergy diagnosis of the animal.

13. The method of claim 1 , wherein the one or more allergens comprise at least one of Timothy grass, Ragweed, and D. Farinae.

14. The method of claim 13, wherein the one or more allergens comprise at least two of Timothy grass, Ragweed, and D. Farinae.

15. The method of claim 14, wherein the one or more allergens comprise Timothy grass, Ragweed, and D. Farinae.

16. A method for determining an allergy status of an animal, comprising: determining an immunoglobin E (IgE) level of the animal, wherein the IgE level corresponds to one or more allergens that induce an allergy condition in the animal; determining an immunologic sensitivity of the animal to the one or more allergens based on the IgE level; and determining that the allergy status of the animal is positive or negative based on the immunologic sensitivity of the animal.

17. The method of claim 16, further comprising applying a topical application compound to the animal when the allergy status of the animal is positive, wherein the topical application compound is formulated to reduce the immunologic sensitivity of the animal to the one or more allergens.

18. The method of claim 17, wherein the topical application compound comprises one or more plant-based allergen selected from the group consisting of Ash, Olive, Cedar, Cypress, luniper,Attorney Docket: 091663.0105Cottonwood, Elm American, Eucalyptus, Maple, Box Elder, Melaleuca, Mesquite, Mulberry, Oak Mix, Alder, Birch, Pecan, Walnut, Palm, Pepper Tree, Pine, Queen Palm, Sycamore, Walnut, Willow, Orange, Hazelnut, Cocklebur, Dog Fennel, Dock, Sorrel Mix, Golden Rod, Lamb’s Quarter, Marsh Elder, Mugwort, Dandelion, Sagebrush, English Plant, Nettle, Pigweed, Plantain, Ragweed, Russian Thistle, Scale, Wing, Bahai grass, Bermuda grass, Johnson grass, Timothy grass, Brome grass, Fescue grass, Kentucky Bluegrass, Orchard grass, Red Top grass, Rye grass, Sweet Vernal grass, or combinations thereof.

19. The method of claim 17, wherein the topical application compound comprises one or more mold or fungus-based allergen selected from the group consisting of Alternaria, Aspergillus, Cladosporium, Fusarium, Malassezia, Mucor, Penicillium, Stemphylium solani, or combinations thereof.

20. The method of claim 17, wherein the topical application compound comprises one or more mite or insect-based allergen selected from the group consisting of Black Ant, Cockroach, House Fly, D. farinae, D. pteronyssinus, Tyrophagus, or combinations thereof.

21. The method of claim 17, wherein the topical application compound comprises one or more manufactured allergen.

22. The method of claim 17, further comprising: determining a first dose of the topical application compound based on one or more of a weight, a species, a breed, a gender, a preexisting condition, or the allergy status of the animal; and applying the first dose of the topical application compound when the allergy status of the animal is positive.

23. The method of claim 22, further comprising: applying the first dose of the topical application compound to the animal for a first treatment interval; and applying a second dose of the topical application compound to the animal for a second treatment interval occurring after the first treatment interval, wherein a first concentration of theAttorney Docket: 091663.0105 first dose of the topical application compound is less than a second concentration of the second dose of the topical application compound.

24. The method of claim 23, further comprising applying a third dose of the topical application compound to the animal for a third treatment interval occurring after the second treatment interval, wherein the second concentration of the second dose of the topical application compound is less than a third concentration of the third dose of the topical application compound.

Images